[ad_1]
Medytox Building and Daewoong Pharmaceutical Headquarters located in Gangnam-gu, Seoul. Yunhap news
The ‘Botox War’ between Daewoong Pharm and Medytox is a point of view. The two companies redistributed a press release on the 29th and demanded an apology from each other.
Daewoong Pharmaceutical and Medytox are in a lawsuit over the source of the strain of a botulinum toxin formulation called ‘Botox’. In position data released that day, Daewoong Pharmaceutical announced that it will request the United States Food and Drug Administration (FDA) to investigate the botulinum toxin formulation of Medytox (Innotox).
Then Medytox also released its position data, saying, “We welcome Daewoong Pharmaceutical’s decision,” saying, “I hope to reveal the truth.”
Daewoong Pharmaceutical headquarters building, which has been in dispute with Botox for 5 years since 2016. Yunhap news
The background to the dispute between the two companies dates back to last month. The United States International Trade Commission (ITC) issued a final decision on the alleged infringement of Daewoong Pharmaceutical trade secrets filed by Medytox on December 16 last year. ‘Daewoong Pharmaceutical’s botulinum toxin formulation’ Nabota (US product names bulletin) ‘was said to violate section 337 of the Customs Act.
In the process of making the decision at the time, ITC decided that Daewoong Pharmaceutical had brought the Medytox strain. The sentence was based on a witness statement from Professor Paul Keim of Northern Arizona University.
At the same time, however, ITC saw that the botulinum strain was not a trade secret. In the final ruling it was stated that “we judge that the Meditox strain does not qualify as a trade secret.”
Daewoong “Petition to US FDA” … Medytox “Very welcome”
Medytox Building located in Gangnam-gu, Seoul. Yunhap news
Daewoong Pharmaceutical, which was shot, was fought back. On the 18th, the Ministry of Food and Drug Safety (Ministry of Food and Drug Safety) canceled the approval on the 18th because it judged that Medytox’s Innotex had obtained the approval of the article and the change of medication illegally. Accordingly, Daewoong Pharmaceutical announced a plan on the 29th in which the US pharmaceutical authorities would ask the US medical authorities to investigate Medytox’s Botox formulation.
Daewoong Pharmaceutical said: “The US ITC is claiming jurisdiction over this lawsuit because Allergan, a US pharmaceutical company (which owns the rights to sell the Medytox Botox formulation in the US), sells Innotox. in the US it will disappear.
Medytox-Daewoong Pharmaceutical’s Botox Ingredient Dispute Magazine. Yunhap news
Daewoong Pharmaceutical sent five public inquiries, saying Innotox’s safety test data was fabricated.
Medytox didn’t stay still. Immediately after submitting the admission data, he urged Daewoong Pharmaceutical to “rush to submit a petition to the US FDA.” “If the FDA launches an investigation, the whole truth will be revealed.” Furthermore, he said: “We welcome the position of Daewoong Pharmaceutical (which is petitioning the FDA). Through this, the false claims of Daewoong Pharmaceutical will be revealed.”
Reporter Moon Hee-cheol [email protected]
[ad_2]
